Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905427 | 1.00 | HSD17B10 (0.42) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL16584822 | 1.00 | HSD17B10 (0.42) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL12295976 | 0.87 | HDAC8 (0.37) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL1780336 | 0.87 | HDAC8 (0.37) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL20054456 | 0.87 | HDAC8 (0.37) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL16342374 | 0.87 | HDAC8 (0.37) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL5782185 | 0.86 | HSD17B10 (0.44) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL19388647 | 0.86 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL18094067 | 0.86 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL789367 | 0.86 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2024-10-31 | — | — | US | disclosed |
| WO-2024133560-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | DARK BLUE THERAPEUTICS LTD (GB) | 2024-06-27 | — | — | WO | disclosed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-4326724-A1 | COMPOUND AS ADENOSINE A2A RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2024-02-28 | — | — | EP | disclosed |
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| CN-110698481-B | Heteroaryl pyridone and aza-pyridone amide compounds | 豪夫迈·罗氏有限公司 | 2023-02-28 | — | — | CN | disclosed |
| WO-2023004376-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20220340595-A1 | MACROCYCLIC INDOLES AS MCL-1 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-10-27 | — | — | US | disclosed |
| CN-110845520-B | Macrocyclic indoles as MCL-1 inhibitors | 苏州亚盛药业有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-20060205672-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2006-09-14 | — | — | US | disclosed |
| US-7012066-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2006-03-14 | — | — | US | disclosed |
| CN-1633446-A | Novel peptides as inhibitors of hepatitis C virus NS 3-serine protease | SCHERING CORP (US) | 2005-06-29 | — | — | CN | disclosed |
| US-20040254117-A9 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON PHARMACEUTICALS LLC | 2004-12-16 | — | — | US | disclosed |
| EP-1481000-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20030216325-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SAKSENA ANIL K | 2003-11-20 | — | — | US | disclosed |
| WO-2003062265-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205672-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | HSD17B10 1968/4885HDAC8 3598/4885SMN1; SMN2 3286/4885 |
| US-20030216325-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | HSD17B10 1968/4885HDAC8 3598/4885SMN1; SMN2 3286/4885 |
| US-20220340595-A1 | MACROCYCLIC INDOLES AS MCL-1 INHIBITORS | MCL1, BCL2A1, BCL2L1 | HSD17B10 3784/4885HDAC8 2033/4885SMN1; SMN2 1427/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | HSD17B10 1968/4885HDAC8 3598/4885SMN1; SMN2 3286/4885 |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | SUMO1, SUMO3, SUMO2 | HSD17B10 2345/4885HDAC8 2327/4885SMN1; SMN2 3718/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | HSD17B10 1332/4885HDAC8 1126/4885SMN1; SMN2 4141/4885 |
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | HSD17B10 3784/4885HDAC8 2033/4885SMN1; SMN2 1427/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | HSD17B10 1968/4885HDAC8 3598/4885SMN1; SMN2 3286/4885 |
| US-20040254117-A9 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | HSD17B10 1968/4885HDAC8 3598/4885SMN1; SMN2 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.